文献速递神经肿瘤

患者中心型脑膜瘤特异性生活质量问卷的开发与验证

Development and validation of a patient-centered, meningioma-specific quality-of-life questionnaire.
PubMed 文献 · J Neurosurg · 2021-05-14

本研究采用标准化患者中心方法开发并验证脑膜瘤特异性生活质量问卷(MQOL)。经条目生成(30例患者、12名照护者、8名医疗提供者)、条目精简(60例患者)和验证(162例患者)三阶段,最终形成含70个条目、9个领域的问卷。各领域Cronbach's α为0.61–0.91,聚合效度与区分效度(p=1.45E-11)均获支持。

要点

  • MQOL含70条目、9领域,平均11分钟完成。
  • 各领域Cronbach's α为0.61–0.91,信度可接受。
  • 极端组检验p=1.45E-11,可区分不同患者组。

核心结论

  • MQOL是经验证、可靠且可行的脑膜瘤患者生活质量评估工具。

研究设计与样本

  • 问卷开发分条目生成、条目精简和验证三阶段。
  • 条目生成纳入30例患者、12名非正式照护者和8名医疗提供者进行半结构化访谈。
  • 条目精简纳入60例患者,采用临床影响法、多重对应分析和层次聚类分析。
  • 验证阶段纳入162例患者,评估极端组效度、与SF-36、FACT-Br和EQ-5D的聚合效度及重测信度。

主要发现

  • 最终问卷含70个条目,代表9个领域。
  • 各领域Cronbach's α范围为0.61–0.91。
  • 聚合效度检验显示结构效度,极端组检验p=1.45E-11。
  • 问卷平均完成时间11分钟。

临床怎么用

  • MQOL可用于临床和研究场景评估脑膜瘤患者健康相关生活质量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Meningiomas can have significant impact on health-related quality of life (HRQOL). Patient-centered, disease-specific instruments for assessing HRQOL in these patients are lacking. To this end, the authors sought to develop and validate a meningioma-specific HRQOL questionnaire through a standardized, patient-centered questionnaire development methodology. METHODS: The development of the questionnaire involved three main phases: item generation, item reduction, and validation. Item generation consisted of semistructured interviews with patients (n = 30), informal caregivers (n = 12), and healthcare providers (n = 8) to create a preliminary list of items. Item reduction with 60 patients was guided by the clinical impact method, multiple correspondence analysis, and hierarchical cluster analysis. The validation phase involved 162 patients and collected evidence on extreme-groups validity; concurrent validity with the SF-36, FACT-Br, and EQ-5D; and test-retest reliability. The questionnaire takes on average 11 minutes to complete. RESULTS: The meningioma-specific quality-of-life questionnaire (MQOL) consists of 70 items representing 9 domains. Cronbach's alpha for each domain ranged from 0.61 to 0.91. Concurrent validity testing demonstrated construct validity, while extreme-groups testing (p = 1.45E-11) confirmed the MQOL's ability to distinguish between different groups of patients. CONCLUSIONS: The MQOL is a validated, reliable, and feasible questionnaire designed specifically for evaluating QOL in meningioma patients. This disease-specific questionnaire will be fundamentally helpful in better understanding and capturing HRQOL in the meningioma patient population and can be used in both clinical and research settings.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Baba A, Saha A, McCradden MD, et al. Development and validation of a patient-centered, meningioma-specific quality-of-life questionnaire. J Neurosurg. 2021. PMID: 33990085. doi:10.3171/2020.11.JNS201761

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。